Abstract

Aims/hypothesisLate-onset type 1 diabetes can be difficult to identify. Measurement of endogenous insulin secretion using C-peptide provides a gold standard classification of diabetes type in longstanding diabetes that closely relates to treatment requirements. We aimed to determine the prevalence and characteristics of type 1 diabetes defined by severe endogenous insulin deficiency after age 30 and assess whether these individuals are identified and managed as having type 1 diabetes in clinical practice.MethodsWe assessed the characteristics of type 1 diabetes defined by rapid insulin requirement (within 3 years of diagnosis) and severe endogenous insulin deficiency (non-fasting C-peptide <200 pmol/l) in 583 participants with insulin-treated diabetes, diagnosed after age 30, from the Diabetes Alliance for Research in England (DARE) population cohort. We compared characteristics with participants with retained endogenous insulin secretion (>600 pmol/l) and 220 participants with severe insulin deficiency who were diagnosed under age 30.ResultsTwenty-one per cent of participants with insulin-treated diabetes who were diagnosed after age 30 met the study criteria for type 1 diabetes. Of these participants, 38% did not receive insulin at diagnosis, of whom 47% self-reported type 2 diabetes. Rapid insulin requirement was highly predictive of severe endogenous insulin deficiency: 85% required insulin within 1 year of diagnosis, and 47% of all those initially treated without insulin who progressed to insulin treatment within 3 years of diagnosis had severe endogenous insulin deficiency. Participants with late-onset type 1 diabetes defined by development of severe insulin deficiency had similar clinical characteristics to those with young-onset type 1 diabetes. However, those with later onset type 1 diabetes had a modestly lower type 1 diabetes genetic risk score (0.268 vs 0.279; p < 0.001 [expected type 2 diabetes population median, 0.231]), a higher islet autoantibody prevalence (GAD-, islet antigen 2 [IA2]- or zinc transporter protein 8 [ZnT8]-positive) of 78% at 13 years vs 62% at 26 years of diabetes duration; (p = 0.02), and were less likely to identify as having type 1 diabetes (79% vs 100%; p < 0.001) vs those with young-onset disease.Conclusions/interpretationType 1 diabetes diagnosed over 30 years of age, defined by severe insulin deficiency, has similar clinical and biological characteristics to that occurring at younger ages, but is frequently not identified. Clinicians should be aware that patients progressing to insulin within 3 years of diagnosis have a high likelihood of type 1 diabetes, regardless of initial diagnosis.

Highlights

  • Type 1 diabetes is classically defined by autoimmune or idiopathic beta cell destruction leading to severe insulin deficiency [1], but this aetiopathological definition is difficult to apply in clinical practice

  • Severe insulin deficiency occurs in 21% of insulin-treated patients diagnosed after 30 years of age and has similar clinical characteristics to young-onset type 1 diabetes Twenty-one per cent (123/583) of insulin-treated participants diagnosed with diabetes after 30 years of age met the study criteria for type 1 diabetes and had severe endogenous insulin deficiency (ESM Fig. 1)

  • Type 1 diabetes defined by severe insulin deficiency has similar clinical and biological characteristics to type 1 diabetes occurring at younger ages

Read more

Summary

Introduction

Type 1 diabetes is classically defined by autoimmune or idiopathic beta cell destruction leading to severe insulin deficiency [1], but this aetiopathological definition is difficult to apply in clinical practice. This research suggests late type 1 diabetes has similar characteristics to young-onset disease and, in contrast to type 1 diabetes defined by autoantibody status alone, continues to have a severe phenotype: 89% were treated with insulin within 1 year of diagnosis, and 11% developed ketoacidosis [4]. This technique does not allow classification of type 1 diabetes at an individual level, and neither islet autoantibodies nor measures of endogenous insulin secretion were available in the UK Biobank population analysed [3]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.